- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00333710
Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD
December 9, 2014 updated by: US Department of Veterans Affairs
The main objective of this proposal is to develop and test the efficacy of two interventions (a telehealth and face-to-face intervention) designed to improve quality of life, self-care, motivation to engage in healthcare, and psychological distress in patients diagnosed with HCV and PTSD.
It is hypothesized that
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Patients with comorbid diagnoses of HCV and PTSD may experience increased risk of diminished quality of life, given that PTSD is associated with poor self-care and medical non-compliance.
To date, no systematic efforts to improve quality of life in this high-risk population have been documented.
The main objective of this proposal is to develop and test the feasibility and efficacy of two cognitive-behavioral interventions (a telehealth intervention and a face-to-face intervention) designed to improve quality of life, self-care, motivation to engage in healthcare, and psychological distress in patients diagnosed with HCV and PTSD.
A secondary objective is to evaluate the cost effectiveness of the interventions.
I plan to develop the interventions, pilot test them, and deliver the refined treatments to veterans with HCV and PTSD.
Participants will be 70 patients from VA Boston who meet study criteria.
Assessment will occur at pre-treatment, post-treatment, and 3- and 6-month follow-up.
Assessments will measure quality of life, self-care, motivation to engage in healthcare, and psychological distress.
Analyses will examine study feasibility, the effects of the treatment conditions, and the cost effectiveness of the interventions.
It is hypothesized that the telephone and face-to-face intervention will improve outcomes, as compared to treatment as usual, but that the participants will be more satisfied with the telephone intervention.
In addition, it is predicted that the telephone condition will be cost effective as compared to the face-to-face intervention
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- VA Medical Center, Jamaica Plain Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of hepatitis C
- Clinical diagnosis of posttraumatic stress disorder
- Need to have access to a telephone
Exclusion Criteria:
- Life threatening or acute illness
- Current alcohol or substance dependence
- Currently prescribed interferon treatment
- No access to a telephone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Individual face-to-face contact
Individual face-to-face contact treatment
|
Individual face-to-face contact with educational and goal setting components
|
|
Experimental: Individual telephone contact
Individual telephone contact treatment
|
Individual telephone contact with educational and goal setting components
|
|
No Intervention: Control condition/treatment as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hepatitis C Virus Knowledge Questionnaire
Time Frame: pre-treatment, post-treatment
|
This is a 62-item measure which assesses knowledge of the hepatitis C Virus.
Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge
|
pre-treatment, post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Amy Silberbogen, PhD, VA Medical Center, Jamaica Plain Campus
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
June 2, 2006
First Submitted That Met QC Criteria
June 2, 2006
First Posted (Estimate)
June 6, 2006
Study Record Updates
Last Update Posted (Estimate)
December 15, 2014
Last Update Submitted That Met QC Criteria
December 9, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Hepatitis
- Hepatitis A
- Hepatitis C
- Stress Disorders, Post-Traumatic
- Chronic Disease
Other Study ID Numbers
- F4120-V
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.